| Autor: |
Ceriello A; IRCCS MultiMedica, Polo Scientifico e Tecnologico, 20138 Milan, Italy., Prattichizzo F; IRCCS MultiMedica, Polo Scientifico e Tecnologico, 20138 Milan, Italy. Electronic address: francesco.prattichizzo@multimedica.it., Berra CC; IRCCS MultiMedica, Department of Diabetes, Milan, Italy., Caballero AE; Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
The lancet. Diabetes & endocrinology [Lancet Diabetes Endocrinol] 2023 Dec; Vol. 11 (12), pp. 894-895. |
| DOI: |
10.1016/S2213-8587(23)00289-9 |
| Abstrakt: |
Competing Interests: AC received consulting fees from AstraZeneca, Bayer, Eli Lilly, Elsevier, Novo Nordisk, Roche Diagnostics, Sanofi, and Servier; received payment or honoraria for lectures from Berlin Chemie, Merck, Novo Nordisk, and Roche Diagnostics; and was on the advisory board of Eli Lilly. FP received honoraria for lectures from Berlin-Chemie. AEC has been a member of scientific advisory boards for AstraZeneca, Boehringer-Ingelheim, Novo Nordisk, Sanofi-Aventis, and Eli Lilly. CCB declares no competing interests. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
